Summary

This article discusses findings from this phase III, multicenter, parallel-group, double-blind, randomized placebo-and active-controlled trial [NCT00696241]. The purpose of this study was to compare the BP lowering effects of azilsartan medoxomil with olmesartan medoxomil and placebo over a period of 6 weeks in patients with primary hypertension.